S.C. hospitals partner to reduce healthcare-related infections

March 2009
Healthcare Purchasing News;Mar2009, Vol. 33 Issue 3, p37
Trade Publication
The article reports on South Carolina Healthcare Quality Trust, the partnership of South Carolina's (S.C.) private and university research hospitals to identify and curb hospital infections, announced in February 2009. The trust comprises of the Health Sciences South Carolina, S.C. Hospital Association and the Premier healthcare alliance. The trust plans to create a web site where hospitals can research the causes and prevention of healthcare-related infections.


Related Articles

  • CIPROFLOXACIN: a highly active fluoroquinolone with a wide range of gram-negative and gram-positive activity.  // Managed Healthcare Executive;Jun2002 Supplement 1, Vol. 12 Issue 6, p4 

    Analyzes the properties and medical capabilities of ciprofloxacin, a highly active fluoroquinolone. Availability of the drug in tablets and suspension formulation; Benefits of the drug; Potential to treat more types of community and hospital-acquired infections.

  • Daily antibiotic cost of nosocomial infections in a Turkish university hospital. Inan, Dilara; Saba, Rabin; Gunseren, Filiz; Ongut, Gozde; Turhan, Ozge; Nevzat Yalcin, Ata; Mamikoglu, Latife // BMC Infectious Diseases;2005, Vol. 5 Issue 1, p5 

    Background: Many studies associated nosocomial infections with increased hospital costs due to extra days in hospital, staff time, extra investigations and drug treatment. The cost of antibiotic treatment for these infections represents a significant part of hospital expenditure. This...

  • Nosocomial infections resistant to vancomycin are on the rise. Rodman, Morton J.; Hurley, Mary Lou // RN;Nov93, Vol. 56 Issue 11, p85 

    Reports on the increase of vancomycin-resistant enterococci (VRE), a kind of bacteria which causes nosocomial infection. Publication of study entitled `Emergence of Vancomycin-Resistant Enterococci in New York City' by T. Frieden, S. Munsiff and others in the 1993 issue of the `Lancet'...

  • Antibiotic combinations more efficacious than ceftazidime in treating hospital-acquired and...  // Formulary;Oct95, Vol. 30 Issue 10, p563 

    Reports that the broad-spectrum antibiotic combination of piperacillin sodium and tazobactam sodium (Zosyn) is more effective than ceftazidime in treating nosocomial respiratory tract and neutropenic infections. Related studies; Hypothesis on Zosyn performance.

  • Recommended guidelines for controlling nosocomial diarrhea.  // Brown University Long-Term Care Quality Letter;6/12/95, Vol. 7 Issue 11, p4 

    Presents guidelines for treating nosocomial diarrhea. Dangers of nosocomial diarrhea; Causes and risk factors; Method of control. INSET: Guidelines for controlling nosocomial diarrhea..

  • Current ATS/IDSA guidelines better than before?  // PharmacoEconomics & Outcomes News;4/3/2010, Issue 600, p4 

    The article discusses research on the efficiency of the 2005 guidelines for nosocomial pneumonia management issued by the American Thoracic Society-Infectious Diseases Society of America, by M. Ferrer and colleagues, published in the February 2010 issue of "Clinical Infectious Diseases."

  • Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated Pneumonia... Fagon, Jean-Yves; Chastre, Jean // Annals of Internal Medicine;04/18/2000, Vol. 132 Issue 8, p621 

    Evaluates invasive and nononvasive strategies for the management of the nosocomial infection, ventilator-assisted pneumonia. Diagnostic and therapeutic strategy applied to patients managed with clinical or invasive strategies; Features and organisms associated with ventilator-associated pneumonia.

  • Managing nosocomial UTI. M.O.R. // Cortlandt Forum;05/25/97, Vol. 10 Issue 5, p142 

    Responds to a question related to the management of nosocomial urinary tract infections in hospitalized patients. Administration of antibiotics; Removal of the urinary catheter for effective treatment.

  • Untitled. Moran, Nuala // BioWorld Today;10/16/2013, Vol. 24 Issue 199, p7 

    The article reports that Nimes, France-based Nosopharm SAS has secured financing worth $1.18 million for the development of the NOSO-95, derived from Xenorhabdus genus.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics